An evaluation of written materials for supporting hypertensive patient education and counselling when performing a new medicine service in Poland.
Anti-hypertensive therapy
Medication adherence
New medicine service
Pharmaceutical care
Written educational material
Journal
BMC medical education
ISSN: 1472-6920
Titre abrégé: BMC Med Educ
Pays: England
ID NLM: 101088679
Informations de publication
Date de publication:
10 May 2024
10 May 2024
Historique:
received:
02
11
2023
accepted:
06
05
2024
medline:
11
5
2024
pubmed:
11
5
2024
entrez:
10
5
2024
Statut:
epublish
Résumé
The New Medicine Service (NMS) was developed in England more than ten years ago, as a three-stage consultation led by community pharmacists to support patients taking new medication for a chronic disease. In Poland, the scheme was officially introduced in January 2023. However, its implementation into common practice has been presented with various obstacles, including the need to develop relationships with general practitioners, resolve the payment structure, and provide training with adequate supporting materials. Hence, written materials have been designed for use as an optional tool for counselling patients receiving an NMS in community pharmacies. The present study evaluates the ability of these materials to inform patients about the need to adhere to anti-hypertensive medication. A group of 401 randomly-selected adult visitors to pharmacies and/or healthcare centres were surveyed; one third had hypertension in their history. The structure, grammar and readability of the text achieved the required threshold of 40% according to the Plain Language Index. The designed materials effectively informed the patients about anti-hypertensive medication, reflected in an increased score in a knowledge test, and were rated positively regarding information level, comprehensibility and presentation. The proposed material may serve as an additional, "patient-friendly" educational tool for use as part of an NMS.
Sections du résumé
BACKGROUND
BACKGROUND
The New Medicine Service (NMS) was developed in England more than ten years ago, as a three-stage consultation led by community pharmacists to support patients taking new medication for a chronic disease. In Poland, the scheme was officially introduced in January 2023. However, its implementation into common practice has been presented with various obstacles, including the need to develop relationships with general practitioners, resolve the payment structure, and provide training with adequate supporting materials. Hence, written materials have been designed for use as an optional tool for counselling patients receiving an NMS in community pharmacies.
METHODS
METHODS
The present study evaluates the ability of these materials to inform patients about the need to adhere to anti-hypertensive medication. A group of 401 randomly-selected adult visitors to pharmacies and/or healthcare centres were surveyed; one third had hypertension in their history.
RESULTS
RESULTS
The structure, grammar and readability of the text achieved the required threshold of 40% according to the Plain Language Index. The designed materials effectively informed the patients about anti-hypertensive medication, reflected in an increased score in a knowledge test, and were rated positively regarding information level, comprehensibility and presentation.
CONCLUSION
CONCLUSIONS
The proposed material may serve as an additional, "patient-friendly" educational tool for use as part of an NMS.
Identifiants
pubmed: 38730316
doi: 10.1186/s12909-024-05523-x
pii: 10.1186/s12909-024-05523-x
doi:
Substances chimiques
Antihypertensive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
521Informations de copyright
© 2024. The Author(s).
Références
Elliott RA, Boyd MJ, Tanajewski L, Barber N, Gkountouras G, Avery AJ, et al. New medicine service’: supporting adherence in people starting a new medication for a long-term condition: 26-week follow-up of a pragmatic randomised controlled trial. BMJ Qual Saf. 2020;29:286–95. https://doi.org/10.1136/bmjqs-2018-009177
doi: 10.1136/bmjqs-2018-009177
Hovland R, Bremer S, Frigaard C, Henjum S, Faksvåg PK, Saether EM, et al. Effect of a pharmacist-led intervention on adherence among patients with a first-time prescription for a cardiovascular medicine: a randomized controlled trial in Norwegian pharmacies. Int J Pharm Pract. 2020;28:337–45. https://doi.org/10.1111/ijpp.12598
doi: 10.1111/ijpp.12598
Elliott RA, Boyd MJ, Salema NE, Davies J, Barber N, Mehta RL, et al. Supporting adherence for people starting a new medication for a long-term condition through community pharmacies: a pragmatic randomised controlled trial of the new medicine service. BMJ Qual Saf. 2016;25:747–58. https://doi.org/10.1136/bmjqs-2015-004400
doi: 10.1136/bmjqs-2015-004400
Waszyk-Nowaczyk M, Jasińska-Stroschein M, Drozd M, Dymek J, Stankiewicz A, Jędra A. Guidelines for performing new medical pharmaceutical service. Position of the team for the standardization of pharmaceutical care of the chamber of pharmacy and the Polish pharmaceutical society. Warszawa: Naczelna Izba Aptekarska; 2024, https://opiekafarmaceutyczna.nia.org.pl/ [Accessed 11 February 2024].
Waszyk-Nowaczyk M, Dymek J, Drozd M, Sierpniowska O, Stankiewicz A, Jędra A, et al. New medicine service as support for medication adherence by chronically ill patients. Farm Pol. 2023;79:281–8. https://doi.org/10.32383/farmpol/172894
doi: 10.32383/farmpol/172894
Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76:2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010
doi: 10.1016/j.jacc.2020.11.010
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–37. https://doi.org/10.1093/eurheartj/ehab484
World Health Organization. Disease burden and mortality estimates. www.who.int/healthinfo/global_burden_disease/estimates/en [Accessed 4 June 2023].
Świątoniowska-Lonc N, Polański J, Mazur G, Jankowska-Polańska B. Impact of beliefs about medicines on the level of intentional non-adherence to the recommendations of elderly patients with hypertension. Int J Environ Res Public Health. 2021;18:2825. https://doi.org/10.3390/ijerph18062825
doi: 10.3390/ijerph18062825
Milosavljevic A, Aspden T, Harrison J. Community pharmacist-led interventions and their impact on patients’ medication adherence and other health outcomes: a systematic review. Int J Pharm Pract. 2018;26(5):387–97. https://doi.org/10.1111/ijpp.12462
doi: 10.1111/ijpp.12462
Jasińska-Stroschein M, Waszyk-Nowaczyk M. Multidimensional interventions on supporting disease management for hospitalized patients with heart failure: the role of clinical and community pharmacists. J Clin Med. 2023;12(8):3037. https://doi.org/10.3390/jcm12083037
doi: 10.3390/jcm12083037
Cavero-Redondo I, Saz-Lara A, Sequí-Dominguez I, Gómez-Guijarro MD, Ruiz-Grao MC, Martinez-Vizcaino V, Álvarez-Bueno C. Comparative effect of eHealth interventions on hypertension management-related outcomes: a network meta-analysis. Int J Nurs Stud. 2021;124:104085. https://doi.org/10.1016/j.ijnurstu.2021.104085
doi: 10.1016/j.ijnurstu.2021.104085
https://nowy-lek.pl/ [Accessed 11 January 2023].
Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874–2071. https://doi.org/10.1097/HJH.0000000000003480
doi: 10.1097/HJH.0000000000003480
https://rejestry.ezdrowie.gov.pl/rpl/search/public [Accessed 2 February 2023].
https://logios.dev [Accessed 2 February 2023].
Raynor DK, Savage I, Knapp P, Henley J. We are the experts: people with asthma talk about their medicine information needs. Patient Educ Couns. 2004;53:167–74. https://doi.org/10.1016/S0738-3991(03)00126-5
doi: 10.1016/S0738-3991(03)00126-5
Hill J, Bird H. The development and evaluation of a drug information leaflet for patients with rheumatoid arthritis. Rheumatology (Oxford). 2003;42:66–70. https://doi.org/10.1093/rheumatology/keg032
doi: 10.1093/rheumatology/keg032
Lee DY, Armour C, Krass I. The development and evaluation of written medicines information for type 2 diabetes. Health Educ Res. 2007;22:918–30. https://doi.org/10.1093/her/cym048
doi: 10.1093/her/cym048
State of the Nation Report. https://kssahsn.net/wp-content/uploads/2023/03/State-of-the-Nation-Report-FINAL.pdf [Accessed 8 August 2023].
Hamrahian SM. Medication non-adherence: a major cause of resistant hypertension. Curr Cardiol Rep. 2020;22(11):133. https://doi.org/10.1007/s11886-020-01400-3
doi: 10.1007/s11886-020-01400-3
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, ESC Scientific Document Group, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–104. https://doi.org/10.1093/eurheartj/ehy339
doi: 10.1093/eurheartj/ehy339
Schulz M, Krueger K, Schuessel K, Friedland K, Laufs U, Mueller WE, et al. Medication adherence and persistence according to different antihypertensive drug classes: a retrospective cohort study of 255,500 patients. Int J Cardiol. 2016;220:668–76. https://doi.org/10.1016/j.ijcard.2016.06.263
doi: 10.1016/j.ijcard.2016.06.263
Fogari R, Zoppi A. Effect of antihypertensive agents on quality of life in the elderly. Drugs Aging. 2004;21:377–93. https://doi.org/10.2165/00002512-200421060-00003
doi: 10.2165/00002512-200421060-00003
Health literacy in. Relation to health outcomes in hypertension: a systematic review. J Atherosclerosis Prev Treat. 2022;13:109–18. https://doi.org/10.53590/japt.02.1040
doi: 10.53590/japt.02.1040
Di Palo KE, Kish T. The role of the pharmacist in hypertension management. Curr Opin Cardiol. 2018;33:382–7. https://doi.org/10.1097/HCO.0000000000000527
doi: 10.1097/HCO.0000000000000527